A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings
Deborah Edwards, Judit Csontos, Michael J Pascoe, Andrew D. Westwell, Elizabeth Gillen, Clare Bennett, Ben Hannigan, Judith Carrier, Jane Harden
preprint DOI: 10.21203/rs.3.rs-2178425/v3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Rapid scoping review Randomized Qualitative |
|---|---|
| Topics | MDMA |
| Key findings | The review reports that ecstasy users employ a wide range of drug-specific, behavioural, and peer-related harm reduction strategies, and that they obtain information from friends, nightclubs, media, leaflets, and user-oriented websites. Of 14 user-oriented websites providing ecstasy-specific harm reduction information, only two cited the evidence used for their content. The authors conclude that adherence to harm reduction can depend on users' goals, such as avoiding comedown or increasing the high, and on previous experience, and that more efficient ways of communicating harms and harm reduction strategies may be needed. |
Abstract
Abstract
Background: Adverse drug reactions (ADRs) can occur due to ecstasy use, and the number of people dying due to drug-related deaths has increased in the past 10 years. Harm reduction strategies could help prevent ADRs or decrease the incidence of life-threatening health consequences due to ecstasy use. However, no reviews have explored the breadth of evidence available on ecstasy harm reduction strategies.
Methods: A rapid scoping review was conducted using adapted JBI methodology to identify the prevalence and nature of harm reduction strategies that ecstasy users employ in recreational settings, with both peer-reviewed research and user-oriented drug information websites explored. Five databases (CINAHL, EMBASE, Medline, PsycINFO, CENTRAL) were searched for English language records from database inception to August 2022. User-oriented websites were identified via the project’s stakeholder group and Google searches.
Results: Twenty reports representing 19 studies (one randomised control trial, nine quantitative descriptive studies and nine qualitative studies) were included. A wide variety of harm reduction strategies were reported, including drug-specific strategies (for example, limiting the amount of ecstasy consumed, buying from trusted sources, drug checking (pill testing)); behavioural strategies (for example, monitoring fluid (water) consumption, taking a rest break to regulate temperature, avoiding alcohol and mixing with other drugs; preloading and post-loading); and peer-related strategies (for example not using alone, looking out for friends). Ecstasy users obtain information on ecstasy’s effects and/or harm reduction practices from a variety of sources including friends, nightclubs, TV news, drug leaflets, music magazines and user-oriented information websites. Fourteen user-oriented websites providing ecstasy-specific harm reduction information were identified, and strategies focused on dosage and frequency of use, interaction with other substances and prevention of health consequences, such as heatstroke, or dehydration among others. However, only two webpages provided citations to the evidence used for the content.
Conclusions: While numerous harm reduction strategies exist, employing them can depend on the users’ overall goal/s which might also encompass avoiding comedown or increasing their high. Moreover, users’ previous experience can influence how and when they adhere to harm reduction. More efficient ways of communicating harms and harm reduction strategies might be needed.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cites 22
- Mood and cognitive effects of ± 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week‐end ‘high’ followed by mid‐week low Addiction July 1, 1997
- Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user Neurology July 25, 2000
- Deaths related to MDMA (ecstasy/molly): Prevalence, root causes, and harm reduction interventions Journal of Substance Use February 20, 2018
- Variability in content and dissolution profiles of MDMA tablets collected in the UK between 2001 and 2018 – A potential risk to users? Drug Testing and Analysis April 22, 2019
- Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database Scientific Reports March 16, 2021
and 17 more in the library